Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells.

[1]  A. Younes,et al.  Current and emerging new treatment strategies for mantle cell lymphoma , 2013, Leukemia & lymphoma.

[2]  O. Hermine,et al.  Emerging agents for the treatment of mantle cell lymphoma , 2012, Expert review of anticancer therapy.

[3]  P. Brousset,et al.  Specific small nucleolar RNA expression profiles in acute leukemia , 2012, Leukemia.

[4]  F. Farzaneh,et al.  Are snoRNAs and snoRNA host genes new players in cancer? , 2012, Nature Reviews Cancer.

[5]  Michelle S. Scott,et al.  From snoRNA to miRNA: Dual function regulatory non-coding RNAs , 2011, Biochimie.

[6]  J. Mattick,et al.  SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. , 2011, RNA.

[7]  M. Mourtada-Maarabouni,et al.  A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. , 2011, Biochemical Society transactions.

[8]  Markus Brameier,et al.  Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs , 2010, Nucleic Acids Res..

[9]  J. Fei,et al.  Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis , 2010, Hematology.

[10]  M. Mourtada-Maarabouni,et al.  Inhibition of Human T-Cell Proliferation by Mammalian Target of Rapamycin (mTOR) Antagonists Requires Noncoding RNA Growth-Arrest-Specific Transcript 5 (GAS5) , 2010, Molecular Pharmacology.

[11]  G. Chrousos,et al.  Noncoding RNA Gas5 Is a Growth Arrest– and Starvation-Associated Repressor of the Glucocorticoid Receptor , 2010, Science Signaling.

[12]  G. Hess.  Temsirolimus for the treatment of mantle cell lymphoma , 2009, Expert review of hematology.

[13]  Geoffrey J. Barton,et al.  Human miRNA Precursors with Box H/ACA snoRNA Features , 2009, PLoS Comput. Biol..

[14]  Wei Zhou,et al.  Implication of snoRNA U50 in human breast cancer. , 2009, Journal of genetics and genomics = Yi chuan xue bao.

[15]  M. Mourtada-Maarabouni,et al.  Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5) , 2008, Journal of Cell Science.

[16]  A. Kibel,et al.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. , 2007, Human molecular genetics.

[17]  M. Mourtada-Maarabouni,et al.  Isolation of genes controlling apoptosis through their effects on cell survival. , 2006, Gene therapy & molecular biology.

[18]  G. Rassidakis,et al.  Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. , 2006, The American journal of pathology.

[19]  Markus Schilhabel,et al.  Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. , 2005, Blood.

[20]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Blenis,et al.  mTOR, translational control and human disease. , 2005, Seminars in cell & developmental biology.

[22]  F. Farzaneh,et al.  The use of gene function to identify the rate-limiting steps controlling cell fate , 2004, Cancer Immunology, Immunotherapy.

[23]  J. Blenis,et al.  mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E , 2004, Molecular and Cellular Biology.

[24]  L. Shaw,et al.  Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses , 2003, Transplantation.

[25]  Tamás Kiss,et al.  7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes , 2001, Nature.

[26]  Z. Darżynkiewicz,et al.  Detection of caspases activation by fluorochrome-labeled inhibitors: Multiparameter analysis by laser scanning cytometry. , 2001, Cytometry.

[27]  O. Meyuhas.  Synthesis of the translational apparatus is regulated at the translational level. , 2000, European journal of biochemistry.

[28]  Z. Darżynkiewicz,et al.  Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. , 2000, Experimental cell research.

[29]  S. Zimmer,et al.  Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. , 2000, Anticancer research.

[30]  J. Steitz,et al.  Classification of gas5 as a Multi-Small-Nucleolar-RNA (snoRNA) Host Gene and a Member of the 5′-Terminal Oligopyrimidine Gene Family Reveals Common Features of snoRNA Host Genes , 1998, Molecular and Cellular Biology.

[31]  T. Yoshino,et al.  Establishment and characterization of a mantle cell lymphoma cell line , 1998, British journal of haematology.

[32]  T. Haystead,et al.  The Mammalian Target of Rapamycin Phosphorylates Sites Having a (Ser/Thr)-Pro Motif and Is Activated by Antibodies to a Region near Its COOH Terminus , 1997, The Journal of Biological Chemistry.

[33]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[34]  N. Sonenberg,et al.  Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E , 1993, Molecular and cellular biology.

[35]  Lennart Philipson,et al.  Genes specifically expressed at growth arrest of mammalian cells , 1988, Cell.

[36]  F. Bertoni,et al.  The cellular origin of mantle cell lymphoma. , 2007, The international journal of biochemistry & cell biology.

[37]  R. Abraham,et al.  Immunopharmacology of rapamycin. , 1996, Annual review of immunology.